PAI-1: A Major Player in the Vascular Dysfunction in Obstructive Sleep Apnea?

Area of Science:

• Cardiovascular Science
• Sleep Medicine
• Molecular Biology

Background:

• Obstructive sleep apnea (OSA) is a common condition linked to increased cardiovascular disease (CVD) risk, yet it remains underdiagnosed and undertreated in clinical practice.
• Current OSA treatments offer limited protection against CVD, necessitating research into novel mechanisms and therapies.
• Plasminogen activator inhibitor-1 (PAI-1) is a key regulator of fibrinolysis and cell migration, with elevated levels associated with cardiovascular events.

Purpose of the Study:

• To review the mechanisms by which OSA and intermittent hypoxia (IH) increase PAI-1 transcription.
• To propose pathways through which PAI-1 contributes to atherosclerosis in OSA patients.
• To identify PAI-1 as a potential therapeutic target for OSA-related CVD.

Main Methods:

• Comprehensive literature review.
• Analysis of molecular mechanisms linking intermittent hypoxia to PAI-1 expression.
• Exploration of PAI-1's role in endothelial dysfunction and atherosclerosis.

Main Results:

• Intermittent hypoxia in OSA enhances PAI-1 transcription through complex regulatory pathways.
• PAI-1 promotes atherosclerosis in OSA via both antifibrinolytic-independent and -dependent mechanisms.
• Elevated PAI-1 levels are observed in OSA patients, suggesting a direct link to the condition.

Conclusions:

• PAI-1 plays a significant role in the development of atherosclerosis in the context of obstructive sleep apnea.
• Targeting PAI-1 may offer a novel therapeutic strategy for managing cardiovascular complications in OSA patients.
• Further research is warranted to elucidate the precise molecular interactions and validate PAI-1 as a therapeutic target.